BURLINGAME, Calif. --(BUSINESS WIRE)--Mar. 31, 2020-- Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in

- Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, Calif. , March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage

Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients continue to experience symptoms even when adherent to ICS/LABA treatment LONDON --(BUSINESS WIRE)--Feb.

Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9% to $70.3 million in the fourth quarter of 2019, compared to the same quarter in 2018. BURLINGAME, Calif. --(BUSINESS WIRE)--Feb.

MARINA DEL REY , Calif. and BRISBANE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc.

Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif. --(BUSINESS WIRE)--Oct.

  LONDON --(BUSINESS WIRE)--Oct. 2, 2019-- GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration ( FDA ) seeking an additional indication for the use of once-daily, single-inhaler triple

Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif. --(BUSINESS WIRE)--Jul.

LONDON --(BUSINESS WIRE)--May 2, 2019-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol:

Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif.